

Haematologica
HAEMATOL/2019/219626
Version 3

Clinicopathological features, treatment approaches, and outcomes in
Rosai-Dorfman disease

Gaurav Goyal, Aishwarya Ravindran, Jason R. Young, Mithun V. Shah,
N. Nora Bennani, Mrinal M. Patnaik, Grzegorz S. Nowakowski, Gita
Thanarajasingam, Thomas M. Habermann, Robert Vassallo, Taimur
Sher, Sameer A. Parikh, Karen L. Rech, and Ronald S. Go
Collaborative Groups: Mayo Clinic Histiocytosis Working Group
(Caroline J Davidge-Pitts, W Oliver Tobin, Matthew J Koster, Julio S
Valinotti)

Disclosures: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AbbVie, AstraZeneca, and Ascentage Pharma for clinical studies in which S.A.P is a principal investigator. S.A.P has also participated in advisory board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). G.S.N. has research funding from Celgene, Genentech, Morphosys, Nanostrings, Curis, and Bayer. G.S.N also consults for Morphosys, Bayer, Celgene, Jansen, Roche, and Abbvie. Our institution has received research funding on behalf of M.M.P from Stemline Pharmaceuticals. R.V. has received research funding from Pfizer, Bristol-Myers-Squibb, and Sun Pharma. None of the other authors have any conflict of interest to disclose.

Contributions: G.G. and A.R. collected clinical data; G.G. analyzed the data and wrote the manuscript draft; histopathologic images and text were provided by K.L.R. and A.R.; radiographic images were provided by J.R.Y; M.V.S, N.N.B., M.M.P, G.S.N., G.T., T.M.H., R.V., T.S., S.A.P., and R.S.G. critically revised the manuscript for important intellectual content; and R.S.G. supervised the study. All authors were involved in drafting the manuscript and approved the final version.